NDA 20-357/S-020

Bristol-Myers Squibb
Attention: Warren C. Randolph
Regulatory Science
P.O. Box 4000
Princeton, NJ 08543-4000

19 APR 2001

Dear Mr. Randolph:

Please refer to your supplemental new drug application dated June 13, 2000, received June 19, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Glucophage® (metformin hydrochloride) Tablets, 500 mg, 850, and 1000 mg.

We acknowledge receipt of your submissions dated September 6, 2000, and March 22, 2001.

This supplemental new drug application provides for changes to the **CLINICAL PHARMACOLOGY** and **DOSAGE AND ADMINISTRATION** sections of the package insert to include additional information describing the details of a previously reviewed study on concomitant administration of Glucophage and glyburide for the treatment of obese patients with type 2 diabetes who had failed to achieve adequate glycemic control while on maximal doses of glyburide. This additional information harmonizes the labeling for Glucophage with that of Glucovance (NDA 21-178), a fixed dose combination of metformin and glyburide.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted March 22, 2001).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-357/S-020." Approval of this submission by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call Ms. Jena Weber, Regulatory Project Manager, at (301) 827-6422.

Sincerely,

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research